Pathology News and Research

RSS

Pathology is the study and diagnosis of disease through examination of organs, tissues, bodily fluids, and whole bodies (autopsies). The term also encompasses the related scientific study of disease processes, called General pathology. Medical pathology is divided in two main branches, Anatomical pathology and Clinical pathology. Veterinary pathology is concerned with animal disease whereas Phytopathology is the study of plant diseases.

Data from Phase 3 clinical evaluation of Lymphoseek presented

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that researchers who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek® presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.

14 Dec 2009

NCKUH and NHRI sponsor virology lab in Vietnam Children’s Hospital

A Virology Lab in Children’s Hospital No. 1 (CH1), Ho Chi Minh City, Vietnam, sponsored by National Cheng Kung University Hospital (NCKUH) and National Health Research Institutes (NHRI) in Taiwan was launched on November 11th, 2009.

11 Dec 2009

ThromboGenics initiates Phase II trial of microplasmin for wet AMD

ThromboGenics NV, a biopharmaceutical company focused on innovative medicines for eye disease, vascular disease and cancer, announces today that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD).

11 Dec 2009

Instem opens new office in Shanghai to support Chinese pharmaceutical and R&D market

Instem, a leading provider of early drug development software solutions, announced today the establishment of an office in Shanghai to provide local customer support, service delivery, client management, development and sales support to the Chinese pharmaceutical and wider life sciences R&D market.

11 Dec 2009

Positive results from Genomic Health's Oncotype DX study in breast cancer patients with node-positive disease

Genomic Health, Inc. today announced that The Lancet Oncology published positive results from a study of Oncotype DX(®) in postmenopausal women with node-positive, estrogen receptor-positive breast cancer conducted by the Southwest Oncology Group (SWOG), a National Cancer Institute-supported clinical trials cooperative group.

11 Dec 2009

HST Global and HMD team up to develop curriculum for FIT protocol

HST Global, Inc. (OTCBB: HSTC) today announced a Partnership with Dr. James W. Forsythe to facilitate the development of a curriculum for the licensing and/or certification to administer Dr. Forsythe’s immune therapy in clinics to be built or acquired by HST Global, Inc.

11 Dec 2009

Enzo Biochem and Ikonisys sign agreement to market molecular-based cervical cancer test

Enzo Biochem, Inc. announced today that its Enzo Clinical Lab division has entered into an exclusive marketing partnership covering the States of New York and New Jersey with privately-owned Ikonisys, Inc., of New Haven, CT, relating to Ikonisys’ proprietary oncoFISH® cervical test, a laboratory developed test for cervical cancer prevention.

10 Dec 2009

Researchers investigate bone pathology

The best way to prevent a fracture is to stop bones from reaching the point where they are prone to breaking, but understanding the process of how bones form and mature has been challenging. Now researchers at the University of Houston department of health and human performance have created a process that grows real human bone in tissue culture, which can be used to investigate how bones form and grow.

10 Dec 2009

German researchers study target-oriented methods for children with brain tumor

Brain tumors are the primary cause of cancer mortality in children. Even if a cure is possible, young patients often suffer tremendously from the stressful treatment which can be harmful to the developing brain.

10 Dec 2009

2009 Ward Burdick Award for UAB Director

The director of the University of Alabama at Birmingham (UAB) Center for Metabolic Bone Disease has won the 2009 Ward Burdick Award for Distinguished Service to Clinical Pathology from the American Society for Clinical Pathology (ASCP).

9 Dec 2009

GPEC receives unrestricted grant of $250,000 to study new treatments for breast cancer

Located at Vancouver General Hospital and a partner of the BC Cancer Agency, the Genetic Pathology Evaluation Centre, led by three prominent pathologists, is a recognized world leader in cancer research in the area of biomarker technology. Today, with an additional unrestricted grant of $250,000 from sanofi-aventis, GPEC is ready to make even more scientific breakthroughs.

9 Dec 2009

Researchers describe how PDNF protein prolongs the life of T. cruzi parasite

The parasite Trypanosoma cruzi (or T. cruzi), which causes Chagas' disease, will go to great lengths to evade death once it has infected human host cells, researchers have discovered. In a study published in the November 17 online issue of Science Signaling, the researchers describe how a protein called parasite-derived neurotrophic factor (PDNF) prolongs the life of the T. cruzi parasite by activating anti-apoptotic (or anti-cell-death) molecules in the host cell. These protective mechanisms help to explain how host cells continue to survive despite being exploited by T. cruzi parasites.

9 Dec 2009

Transgenomic's SURVEYOR Scan K-RAS mutation detection kit launched

Transgenomic, Inc. announced today the launch of its SURVEYOR Scan K-RAS kit, the first in a family of mutation detection kits the company plans to offer featuring its proprietary SURVEYOR Nuclease and WAVE® HS DHPLC platform. SURVEYOR Scan technology is a novel approach to mutation detection that uses a PCR amplification reaction and hybridization to form heteroduplex DNA molecules in samples with K-RAS mutation.

9 Dec 2009

Neoprobe completes Phase 3 Lymphoseek clinical trial on breast cancer patients

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, has completed a Phase 3 clinical trial of Lymphoseek® (NEO3-05) with positive results.

9 Dec 2009

New data provide comprehensive review of emerging role of small airways in asthma management

Teva Respiratory, a division of Teva Pharmaceutical Industries Ltd., today announced the publication of four articles in a special supplement of the December issue of the Journal of Allergy and Clinical Immunology (JACI), providing a comprehensive scientific review of the emerging role of the small airways in the understanding and treatment of asthma.

8 Dec 2009

Winner of the 2009 Outstanding Investigator Award for Breast Cancer Research

Calling his work "one of the most important findings in breast cancer and health disparities in the last decade," the American Association for Cancer Research (AACR) has named Charles M. Perou, Ph.D. the 2009 Outstanding Investigator Award for Breast Cancer Research, funded by Susan G. Komen for the Cure-.

8 Dec 2009

H1N1 virus produces pulmonary damage similar to earlier flu pandemics

In fatal cases of 2009 H1N1 influenza, the virus can damage cells throughout the respiratory airway, much like the viruses that caused the 1918 and 1957 influenza pandemics, report researchers from the National Institutes of Health (NIH) and the New York City Office of Chief Medical Examiner.

8 Dec 2009

Social isolation and stress can raise breast cancer risk

Social isolation and related stress could contribute to human breast cancer susceptibility, research from a rat model designed at the University of Chicago to identify environmental mechanisms contributing to cancer risk shows.

8 Dec 2009

Cyntellect and Boston University sign research collaboration agreement

Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today announced it has entered into a research collaboration agreement with the Boston University School of Medicine.

8 Dec 2009

New data from Allos Therapeutics' FOLOTYN trial for PTCL

Allos Therapeutics, Inc. today reported a new analysis of data from the Company’s pivotal PROPEL trial of FOLOTYN™ (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.

7 Dec 2009